Physician time constraints, competing priorities for patients and shortcomings in follow-up initiatives are a few of the top causes of medication non-adherence; a $300 billion source of wasted U.S. healthcare spending every year.
What can pharma brand teams do to improve patient persistence? It begins with an honest assessment of the patient journey and optimization of follow-up programs.
“If persistence is the gold standard by which brand teams measure success investing the right amount of time in the right type of resources is critical. Knowing that half of all new prescriptions don’t get filled, it’s imperative that intensive patient follow up to address concerns, confirm the accuracy of the information they have on hand, and reinforce the value of their therapy and compliance take place before patients go to the pharmacy.”
Read more about the “Top Barriers to Patient Persistence and how pharma can help overcome them,” the third in a series of articles by Curant Health Senior Director of Clinical Services Vickie Andros and Senior Director of Commercial Strategy and Performance Jake Caines in Pharmaceutical Executive.
If you are a brand team representative for a pharmaceutical manufacturer and want to learn more about how Curant Health’s Patient Education and Engagement Resource model aligns stakeholders, improves persistence and patient outcomes, email PEERProgram@curanthealth.com